Observed Signal · Nov 3, 2026 · Earnings Report · Source: Manager Magazin · Impact: 2/5 · Sentiment: Neutral

Evonik Profit Surges, Strengthens Position in BASF Takeover Battle

Executive Signal Summary

Specialty chemicals company Evonik reported a strong third quarter, with adjusted EBITDA up 40% to €629 million and sales up 13% to €3.8 billion. The results bolster Evonik's stance in its ongoing dispute with BASF over a potential takeover. Evonik has rejected BASF's offer of €24.00 per share and remains focused on its independence strategy under interim CEO Claus Rettig. The company is restructuring to boost profitability, including divesting subsidiaries Oxeno and Syneqt, and targeting an ROCE of about 11% by 2029. BASF CEO Markus Kamieth continues to advocate for a merger as a "strong German answer to global competition." Evonik's improved performance comes amid supply disruptions in Asia due to the Middle East crisis, which has increased demand and pricing power.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

While Evonik is a major chemical company, this news is primarily about their financial results and a potential takeover bid, which is not directly related to advertising technology, marketing technology, or digital advertising. The M&A aspect is significant but falls outside the AdTech/MarTech industry relevance criteria.

SIGNAL RADAR

Track Real-Time M&A Signals & Market Shifts

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • Evonik's adjusted EBITDA rose 40% to €629 million in Q3.
  • Evonik's sales increased 13% to €3.8 billion in Q3.
  • Evonik rejected BASF's takeover offer of €24.00 per share.
  • Evonik plans to sell subsidiary Oxeno and prepare sale of Syneqt.
  • Evonik targets ROCE of about 11% by 2029.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Manager Magazin•Published: Nov 3, 2026
Original Coverage Title: “Gewinn und Umsatz steigen: Evonik sieht sich gestärkt im Poker mit BASF”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

M&AOct 22, 2026

Evonik Eyes Ashland Acquisition to Thwart BASF

German specialty chemicals company Evonik is reportedly exploring the acquisition of US-based Ashland, according to two insiders. Ashland, valued at $3.3 billion on the New York Stock Exchange, is seeking buyers under pressure from activist investors. The potential deal is seen as a defensive move against BASF's planned takeover of Evonik, though insiders say the process began before BASF's approach. Evonik's acquisition would make it larger and harder for BASF to absorb. BASF's CEO Markus Kamieth is courting Evonik with job guarantees, pledging no operational layoffs until 2032 and emphasizing a strong German response to global competition. Other financial investors like Advent, Apollo, and Carlyle have also shown interest in Ashland. Evonik has hired Perella Weinberg and JP Morgan as advisors.

Read assessment
Earnings ReportOct 29, 2026

Henkel Posts Double-Digit Sales Growth, Lifts Outlook

Henkel reported a strong third quarter of 2026, with group sales rising 11.0% nominally to €5.713 billion, driven by higher prices and volumes. Organic sales grew 6.5%. Adhesive Technologies led growth with a 7.9% organic increase to €3.027 billion, while Consumer Brands grew 4.8% organically to €2.643 billion (nominal +10.1%), supported by acquisitions of Olaplex and Not Your Mother's. For the first nine months, sales reached €16.061 billion, up 4.3% organically. The company completed five acquisitions announced in 2026, expected to contribute around €1.6 billion. Full-year guidance was raised: organic sales growth now expected at 3-4% (previously 1.5-3.5%), with adjusted EBIT margin around 15%. However, higher material costs (+10%) and restructuring charges (€200-250 million) continue to pressure profitability.

Read assessment
FinancialsNov 4, 2026

Fresenius Raises Annual Targets Again on Generic Drugs

Fresenius, the German healthcare group, has raised its annual profit target for the second time this year, driven by strong performance in its biosimilars division and its Helios hospital chain. The company now expects currency-adjusted core earnings per share growth in the upper half of its 10-15% range, up from previous expectations of around 11.5% EBIT margin. In the third quarter, revenue rose 6% to €5.8 billion, exceeding analyst expectations, while operating profit climbed 11% to €638 million. The biosimilars business grew organically by 29%. To further expand this area, Fresenius recently announced a partnership with Chinese manufacturer WuXi Biologics to access up to 37 new biosimilar candidates over ten years, potentially growing its portfolio from 29 to 66 products. The company also continues to reduce debt, with net financial debt falling to €10.1 billion by end of September.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for M&A in your executive briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime